Author: admin

The Cough in Idiopathic Pulmonary Fibrosis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Cough in Idiopathic Pulmonary Fibrosis Pipeline Insight, 2025“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Cough in Idiopathic Pulmonary Fibrosis Market.

Some of the key takeaways from the Cough in Idiopathic Pulmonary Fibrosis Pipeline Report:

• Companies across the globe are diligently working toward developing novel Cough in Idiopathic Pulmonary Fibrosis treatment therapies with a considerable amount of success over the years.

• Cough in Idiopathic Pulmonary Fibrosis companies working in the treatment market are NeRRe Therapeutics, Trevi Therapeutics, Melius Pharma AB, Boehringer Ingelheim, and others, are developing therapies for the Cough in Idiopathic Pulmonary Fibrosis treatment

• Emerging Cough in Idiopathic Pulmonary Fibrosis therapies in the different phases of clinical trials are- Orvepitant Maleate, Haduvio (nalbuphine ER), ME-015 (Suplatast Tosilate) BI 1839100, and others are expected to have a significant impact on the Cough in Idiopathic Pulmonary Fibrosis market in the coming years.

• In March 2025, Trevi Therapeutics, the U.S.-based company developing nalbuphine extended-release (ER) tablets, announced the completion of enrollment in the Phase 2b clinical trial, known as CORAL. The trial is evaluating the therapy, which is intended to be marketed as Haduvio, in individuals with idiopathic pulmonary fibrosis (IPF) who experience chronic cough. This milestone marks a significant step forward in the development of Haduvio for IPF patients dealing with chronic cough.

• In February 2025, Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on developing Haduvio™ (oral nalbuphine ER) for chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), has announced the completion of patient enrollment in its Phase 2b CORAL trial evaluating Haduvio for chronic cough in IPF patients.

• In January 2025, Mediar Therapeutics entered into a global licensing agreement with Eli Lilly and Company to progress MTX-463 into a Phase II clinical trial for idiopathic pulmonary fibrosis (IPF). MTX-463 is a novel, first-in-class human IgG1 antibody aimed at inhibiting WISP1-mediated fibrotic signaling, which plays a role in multiple debilitating diseases.

• In December 2024, Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on developing the investigational treatment Haduvio™ (oral nalbuphine ER) for chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), has announced a positive result from the planned sample size re-estimation (SSRE) for its ongoing Phase 2b CORAL trial in IPF patients with chronic cough. The outcome indicates that no adjustments are needed to the current sample size for the trial (N=160).

• In August 2024, Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), has announced that the majority of the 60 planned sites for the Phase 2b CORAL trial have been initiated. The trial, which aims to enroll around 160 patients, will include a sample size re-estimation (SSRE) in the fourth quarter of this year, once 50% of patients are evaluable for the primary endpoint. Barring any adjustments, topline results are expected in the first half of 2025.

• In May 2024, Pliant Therapeutics, Inc. (Nasdaq: PLRX) has announced topline results from a 12-week, randomized, double-blind, placebo-controlled trial of bexotegrast (PLN-74809) conducted at Massachusetts General Hospital. The trial evaluated changes in total collagen levels in the lungs of patients with idiopathic pulmonary fibrosis (IPF), a condition marked by excessive collagen buildup in the lungs.

• In March 2024, US-based Seyltx finalized an agreement to acquire Algernon Pharmaceuticals’ chronic cough therapy, ifenprodil (NP-120). Algernon received $2 million and a 20% equity stake in Seyltx as part of the deal. Ifenprodil, an N-methyl-D-aspartate (NMDA) receptor antagonist, specifically targets the NMDA type subunit 2B (GluN2B). Data from the Phase II trial conducted in Australia and New Zealand demonstrated a reduction in cough count among patients with idiopathic pulmonary fibrosis (IPF) and chronic cough compared to baseline.

Cough in Idiopathic Pulmonary Fibrosis Overview

Cough in Idiopathic Pulmonary Fibrosis (IPF) is a common and distressing symptom of this chronic lung disease. IPF causes scarring and thickening of the lung tissue, leading to breathing difficulties and persistent dry, non-productive cough. The exact cause of cough in IPF is not fully understood, but it is believed to result from the irritation caused by the fibrosis (scarring) of the lung tissue, which can trigger the cough reflex. This cough is often persistent, worsening over time, and can significantly impact a patient’s quality of life. Treatment typically focuses on managing symptoms and slowing the progression of IPF.

Get a Free Sample PDF Report to know more about Cough in Idiopathic Pulmonary Fibrosis Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/cough-in-idiopathic-pulmonary-fibrosis-pipeline-insight

Emerging Cough in Idiopathic Pulmonary Fibrosis Drugs Under Different Phases of Clinical Development Include:

• Orvepitant Maleate: NeRRe Therapeutics

• Haduvio (nalbuphine ER): Trevi Therapeutics

• ME-015 (Suplatast Tosilate): Melius Pharma AB

• BI 1839100: Boehringer Ingelheim

Cough in Idiopathic Pulmonary Fibrosis Route of Administration

Cough in Idiopathic Pulmonary Fibrosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

• Oral

• Parenteral

• Intravenous

• Subcutaneous

• Topical

Cough in Idiopathic Pulmonary Fibrosis Molecule Type

Cough in Idiopathic Pulmonary Fibrosis Products have been categorized under various Molecule types, such as

• Monoclonal Antibody

• Peptides

• Polymer

• Small molecule

• Gene therapy

Cough in Idiopathic Pulmonary Fibrosis Pipeline Therapeutics Assessment

• Cough in Idiopathic Pulmonary Fibrosis Assessment by Product Type

• Cough in Idiopathic Pulmonary Fibrosis By Stage and Product Type

• Cough in Idiopathic Pulmonary Fibrosis Assessment by Route of Administration

• Cough in Idiopathic Pulmonary Fibrosis By Stage and Route of Administration

• Cough in Idiopathic Pulmonary Fibrosis Assessment by Molecule Type

• Cough in Idiopathic Pulmonary Fibrosis by Stage and Molecule Type

DelveInsight’s Cough in Idiopathic Pulmonary Fibrosis Report covers around 5+ products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I)

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

• Route of Administration

Further Cough in Idiopathic Pulmonary Fibrosis product details are provided in the report. Download the Cough in Idiopathic Pulmonary Fibrosis pipeline report to learn more about the emerging Cough in Idiopathic Pulmonary Fibrosis therapies

Some of the key companies in the Cough in Idiopathic Pulmonary Fibrosis Therapeutics Market include:

Key companies developing therapies for Cough in Idiopathic Pulmonary Fibrosis are – Algernon Pharmaceuticals, Seyltx Inc., Melius Pharma AB, NeRRe Therapeutics, Trevi Therapeutics, Cellular Sciences, Emphycorp, and others

Cough in Idiopathic Pulmonary Fibrosis Pipeline Analysis:

The Cough in Idiopathic Pulmonary Fibrosis pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Cough in Idiopathic Pulmonary Fibrosis with aggregate therapies developed by each company for the same.

• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Cough in Idiopathic Pulmonary Fibrosis Treatment.

• Cough in Idiopathic Pulmonary Fibrosis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• Cough in Idiopathic Pulmonary Fibrosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Cough in Idiopathic Pulmonary Fibrosis market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Cough in Idiopathic Pulmonary Fibrosis drugs and therapies

Cough in Idiopathic Pulmonary Fibrosis Pipeline Market Drivers

• High Unmet Need, Growing Patient Population, Advancements in Research, Regulatory Support, Increased Investment, are some of the important factors that are fueling the Cough in Idiopathic Pulmonary Fibrosis Market.

Cough in Idiopathic Pulmonary Fibrosis Pipeline Market Barriers

• However, Complex Disease Pathophysiology, Clinical Trial Challenges, Competitive Landscape, and other factors are creating obstacles in the Cough in Idiopathic Pulmonary Fibrosis Market growth.

Scope of Cough in Idiopathic Pulmonary Fibrosis Pipeline Drug Insight

• Coverage: Global

• Key Cough in Idiopathic Pulmonary Fibrosis Companies: NeRRe Therapeutics, Trevi Therapeutics, Melius Pharma AB, Boehringer Ingelheim, and others

• Key Cough in Idiopathic Pulmonary Fibrosis Therapies: Orvepitant Maleate, Haduvio (nalbuphine ER), ME-015 (Suplatast Tosilate) BI 1839100, and others

• Cough in Idiopathic Pulmonary Fibrosis Therapeutic Assessment: Cough in Idiopathic Pulmonary Fibrosis current marketed and Cough in Idiopathic Pulmonary Fibrosis emerging therapies

• Cough in Idiopathic Pulmonary Fibrosis Market Dynamics: Cough in Idiopathic Pulmonary Fibrosis market drivers and Cough in Idiopathic Pulmonary Fibrosis market barriers

Request for Sample PDF Report for Cough in Idiopathic Pulmonary Fibrosis Pipeline Assessment and clinical trials

Table of Contents

1. Cough in Idiopathic Pulmonary Fibrosis Report Introduction

2. Cough in Idiopathic Pulmonary Fibrosis Executive Summary

3. Cough in Idiopathic Pulmonary Fibrosis Overview

4. Cough in Idiopathic Pulmonary Fibrosis- Analytical Perspective In-depth Commercial Assessment

5. Cough in Idiopathic Pulmonary Fibrosis Pipeline Therapeutics

6. Cough in Idiopathic Pulmonary Fibrosis Late Stage Products (Phase II/III)

7. Cough in Idiopathic Pulmonary Fibrosis Mid Stage Products (Phase II)

8. Cough in Idiopathic Pulmonary Fibrosis Early Stage Products (Phase I)

9. Cough in Idiopathic Pulmonary Fibrosis Preclinical Stage Products

10. Cough in Idiopathic Pulmonary Fibrosis Therapeutics Assessment

11. Cough in Idiopathic Pulmonary Fibrosis Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Cough in Idiopathic Pulmonary Fibrosis Key Companies

14. Cough in Idiopathic Pulmonary Fibrosis Key Products

15. Cough in Idiopathic Pulmonary Fibrosis Unmet Needs

16 . Cough in Idiopathic Pulmonary Fibrosis Market Drivers and Barriers

17. Cough in Idiopathic Pulmonary Fibrosis Future Perspectives and Conclusion

18. Cough in Idiopathic Pulmonary Fibrosis Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Cough in Idiopathic Pulmonary Pipeline 2025: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | Algernon Pharma, Seyltx, Melius Pharma, NeRRe Therapeutics, Trevi Therapeutics

The Progressive pulmonary fibrosis market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Progressive pulmonary fibrosis pipeline products will significantly revolutionize the Progressive pulmonary fibrosis market dynamics.

DelveInsight’s “Progressive pulmonary fibrosis Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Progressive pulmonary fibrosis, historical and forecasted epidemiology as well as the Progressive pulmonary fibrosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

To Know in detail about the Progressive pulmonary fibrosis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Progressive pulmonary fibrosis Market Forecast

Some of the key facts of the Progressive pulmonary fibrosis Market Report:

• The Progressive pulmonary fibrosis market size was valued ~USD 1,300 million in the year 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)

• In January 2025, Mediar Therapeutics entered into a global licensing agreement with Eli Lilly and Company to progress MTX-463 into a Phase II clinical trial for idiopathic pulmonary fibrosis (IPF). MTX-463 is a novel human IgG1 antibody specifically designed to inhibit WISP1-driven fibrotic signaling, offering potential treatment for multiple severe fibrotic conditions.

• In October 2024, Trevi Therapeutics, a company focused on developing Haduvio (oral nalbuphine ER) as a potential treatment for chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), has shared updates on its ongoing clinical development programs.

• In September 2024, Aileron Therapeutics announced that enrollment for Cohort 2 in the ongoing Phase Ib clinical trial of LTI-03 in IPF patients has been completed.

• The ATS 2024 International Conference showcased in-depth discussions on Progressive Pulmonary Fibrosis (PPF). Key sessions covered strategies to improve care for patients with combined pulmonary fibrosis and emphysema, research on the protective influence of steroid hormones in pulmonary fibrosis development and progression, insights from cellular genomics of bronchoalveolar lavage in understanding fibrosis mechanisms, and the potential of PEG-FUD as a probe for targeting the pro-fibrotic disease phase.

• In 2023, the United States held the largest market share for Progressive Pulmonary Fibrosis (PPF) among the 7MM, with an estimated market size of approximately USD 1,000 million, which is projected to grow further by 2034.

• In 2023, Germany recorded the highest market size for Progressive Pulmonary Fibrosis (PPF) among EU countries, reaching USD 50 million, whereas Spain had the smallest market size, totaling USD 39 million.

• In 2023, the market size for Progressive Pulmonary Fibrosis (PPF) in Japan was approximately USD 58 million, representing 4% of the total market across the 7MM

• The investigational therapy BI 1015550 is anticipated to be introduced in EU4 and the UK by 2027 and in Japan by 2028, with the potential to alleviate the disease burden of Progressive Pulmonary Fibrosis (PPF) in the coming years.

• According to DelveInsight’s analysis, the total diagnosed prevalent cases of Progressive Pulmonary Fibrosis (PPF) in the 7MM were estimated to be 135,000 in 2023.

• In 2023, the United States recorded the highest number of diagnosed prevalent cases of Progressive Pulmonary Fibrosis (PPF), estimated at 77,000, with projections indicating a future increase.

• Among European countries, Germany reported the highest number of diagnosed prevalent cases of Progressive Pulmonary Fibrosis (PPF) in 2023, with approximately 11,000 cases, followed by the United Kingdom with 10,000 cases. In contrast, Spain had the lowest prevalence, with around 6,000 cases.

• In 2023, Japan recorded approximately 10,000 diagnosed prevalent cases of Progressive Pulmonary Fibrosis (PPF), representing around 8% of the total cases in the 7MM.

• Key Progressive pulmonary fibrosis Companies: Boehringer Ingelheim, Bristol-Myers Squibb, Avalyn Pharma Inc., United Therapeutics, Sunshine Lake Pharma, Endeavor Biomedicines, and others

• Key Progressive pulmonary fibrosis Therapies: Nerandomilast (BI 1015550), BMS-986278, AP01, Inhaled Treprostinil, HEC585, ENV-101, and others

• The Progressive pulmonary fibrosis epidemiology based on type-specific cases analyzed that the highest percentage of prevalent cases was observed in Idiopathic interstitial pneumonias (IIPs) among all other types, in the 7MM countries

Progressive pulmonary fibrosis Overview

Progressive Pulmonary Fibrosis (PPF) is a chronic lung disease characterized by continuous scarring (fibrosis) of lung tissue, leading to worsening lung function and breathing difficulties over time. It is associated with various interstitial lung diseases (ILDs) and progresses regardless of the initial cause. Symptoms include shortness of breath, persistent dry cough, fatigue, and reduced exercise tolerance. PPF has no cure, but treatments such as antifibrotic drugs, oxygen therapy, and pulmonary rehabilitation aim to slow disease progression and improve quality of life.

Get a Free sample for the Progressive pulmonary fibrosis Market Report:

https://www.delveinsight.com/report-store/progressive-pulmonary-fibrosis-ppf-market

Progressive pulmonary fibrosis Epidemiology Segmentation:

The Progressive pulmonary fibrosis market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Prevalence of Progressive pulmonary fibrosis

• Prevalent Cases of Progressive pulmonary fibrosis by severity

• Gender-specific Prevalence of Progressive pulmonary fibrosis

• Diagnosed Cases of Episodic and Chronic Progressive pulmonary fibrosis

Download the report to understand which factors are driving Progressive pulmonary fibrosis epidemiology trends @ Progressive pulmonary fibrosis Epidemiological Insights

Progressive pulmonary fibrosis Market

The dynamics of the Progressive pulmonary fibrosis market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2020-2034.

“Certainly, the clinical pipeline of Progressive pulmonary fibrosis looks not so robust but the market anticipates the launch of emerging drugs in the forecast period (2022-2032). Yet, some of the therapies carry the potential to reach the market sooner if they prove their clinical benefits in their ongoing trials. The potential drugs that can mark a significant change in the upcoming forecast period are in the mid and late stage of development.”

Progressive pulmonary fibrosis Therapies and Key Companies

• Nerandomilast (BI 1015550): Boehringer Ingelheim

• BMS-986278: Bristol-Myers Squibb

• AP01: Avalyn Pharma Inc.

• Inhaled Treprostinil: United Therapeutics

• HEC585: Sunshine Lake Pharma

• ENV-101: Endeavor Biomedicines

To know more about Progressive pulmonary fibrosis treatment, visit @ Progressive pulmonary fibrosis Medications

Progressive pulmonary fibrosis Market Drivers

• Advancement in research and development

• Exponential Market Growth

• Potential biomarkers

• Improvement in the treatment pathways

Progressive pulmonary fibrosis Market Barriers

• Dry clinical pipeline for Progressive pulmonary fibrosis

• Diagnostic Barrier

• Disease understanding challenges

• Pitfalls of epidemiological studies in ILDs

Scope of the Progressive pulmonary fibrosis Market Report

• Study Period: 2020–2034

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Progressive pulmonary fibrosis Companies: Boehringer Ingelheim, Bristol-Myers Squibb, Avalyn Pharma Inc., United Therapeutics, Sunshine Lake Pharma, Endeavor Biomedicines, and others

• Key Progressive pulmonary fibrosis Therapies: Nerandomilast (BI 1015550), BMS-986278, AP01, Inhaled Treprostinil, HEC585, ENV-101, and others

• Progressive pulmonary fibrosis Therapeutic Assessment: Progressive pulmonary fibrosis current marketed and Progressive pulmonary fibrosis emerging therapies

• Progressive pulmonary fibrosis Market Dynamics: Progressive pulmonary fibrosis market drivers and Progressive pulmonary fibrosis market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Progressive pulmonary fibrosis Unmet Needs, KOL’s views, Analyst’s views, Progressive pulmonary fibrosis Market Access and Reimbursement

Discover more about therapies set to grab major Progressive pulmonary fibrosis market share @ Progressive pulmonary fibrosis Treatment Landscape

Table of Contents

1. Progressive pulmonary fibrosis Market Report Introduction

2. Executive Summary for Progressive pulmonary fibrosis

3. SWOT analysis of Progressive pulmonary fibrosis

4. Progressive pulmonary fibrosis Patient Share (%) Overview at a Glance

5. Progressive pulmonary fibrosis Market Overview at a Glance

6. Progressive pulmonary fibrosis Disease Background and Overview

7. Progressive pulmonary fibrosis Epidemiology and Patient Population

8. Country-Specific Patient Population of Progressive pulmonary fibrosis

9. Progressive pulmonary fibrosis Current Treatment and Medical Practices

10. Progressive pulmonary fibrosis Unmet Needs

11. Progressive pulmonary fibrosis Emerging Therapies

12. Progressive pulmonary fibrosis Market Outlook

13. Country-Wise Progressive pulmonary fibrosis Market Analysis (2020–2034)

14. Progressive pulmonary fibrosis Market Access and Reimbursement of Therapies

15. Progressive pulmonary fibrosis Market Drivers

16. Progressive pulmonary fibrosis Market Barriers

17. Progressive pulmonary fibrosis Appendix

18. Progressive pulmonary fibrosis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Progressive pulmonary fibrosis Market on Track for Major Expansion by 2034According to DelveInsight | Bristol-Myers Squibb, Avalyn Pharma Inc., Boehringer Ingelheim, United Therapeutics, Sunshine Lake